Related Experiment Video
Updated: Jan 14, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Eudragit S100-coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate's oral bioavailability
Maged K Elsayad1, Abdulsalam M Kassem1,2, Elsaied H Barakat1
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Nasr City 11751, Cairo, Egypt.
Objectives:
Dabigatran etexilate (DAB), a direct thrombin inhibitor, exhibits limited oral bioavailability (6%-7%), mostly attributable to pH-dependent solubility. To address this issue, Eudragit S100 (EU)-coated liposomes were engineered to safeguard DAB-loaded nanocarriers in the stomach and provide targeted release in the intestine, where absorption occurs through several mechanisms.
Methods:
Liposomal vesicles were prepared using the conventional thin film hydration method. The developed formulations were subjected to physicochemical characterization, which included Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), zeta potential analysis, particle size measurement, polydispersity index (PDI) assessment, entrapment efficiency (EE%), and transmission electron microscopy (TEM).
Key Findings:
The selected formulation, EU@DAB-Lip4, exhibited advantageous properties: minimal particle size (136.9 nm), high EE (92.67%), and colloidal stability (zeta potential -17.3 mV). In vitro release demonstrated pH-responsive behaviour, with low gastric release (12.8% at 2 hr) and enhanced intestinal release (75.5% at pH 7.4). Pharmacokinetic studies in rats demonstrated a 5.6-fold and 2.7-fold enhancement in bioavailability for EU@DAB-Lip4 relative to DAB-Lip and DAB suspension, respectively, as indicated by elevated Cmax (2664 vs. 891 and 554 ng/ml) and AUC₀-∞ (21 020 vs. 7236 and 3749 ng.hr/ml).
Conclusions:
EU-coated liposomes constitute a viable platform for enhancing DAB bioavailability and therapeutic efficacy.
Related Concept Videos
Bioavailability Enhancement: Drug Permeability Enhancement
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Bioavailability Enhancement: Drug Solubility Enhancement
Routes of Drug Administration: Enteral
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Drug Delivery: Enteral Route

